Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways

APOLLO Research Network

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

We present a deep proteogenomic profiling study of 87 lung adenocarcinoma (LUAD) tumors from the United States, integrating whole-genome sequencing, transcriptome sequencing, proteomics and phosphoproteomics by mass spectrometry, and reverse-phase protein arrays. We identify three subtypes from somatic genome signature analysis, including a transition-high subtype enriched with never smokers, a transversion-high subtype enriched with current smokers, and a structurally altered subtype enriched with former smokers, TP53 alterations, and genome-wide structural alterations. We show that within-tumor correlations of RNA and protein expression associate with tumor purity and immune cell profiles. We detect and independently validate expression signatures of RNA and protein that predict patient survival. Additionally, among co-measured genes, we found that protein expression is more often associated with patient survival than RNA. Finally, integrative analysis characterizes three expression subtypes with divergent mutations, proteomic regulatory networks, and therapeutic vulnerabilities. This proteogenomic characterization provides a foundation for molecularly informed medicine in LUAD.

Original languageEnglish
Article number100819
JournalCell Reports Medicine
Volume3
Issue number11
DOIs
StatePublished - 15 Nov 2022
Externally publishedYes

Keywords

  • TP53
  • cancer
  • immune
  • lung adenocarcinoma
  • proteogenomics
  • proteomics
  • subtype
  • survival
  • transcriptomics
  • whole genome

Fingerprint

Dive into the research topics of 'Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways'. Together they form a unique fingerprint.

Cite this